Table of Contents
Ready to See Results?
From strategy through execution, Atlantic Health Strategies integrates compliance, operations, and growth into durable, measurable results. Let’s put our expertise to work for your organization.
What behavioral health M&A advisory actually covers
Behavioral health M&A advisory covers regulatory due diligence, licensure and accreditation transferability analysis, payer contract and Conditions of Participation review, quality-of-earnings support, and post-close integration planning. Buy-side work concentrates on finding the risks that reprice the deal. Sell-side work concentrates on removing those risks before the teaser ever goes out.
The market is not what it was in 2021. Mertz Taggart counted 31 behavioral health deals in Q2 2025, down from 48 in Q1, and 180 total transactions for the full year 2025, up slightly from 176 in 2024. Lenders are running what one report called “forensic” diligence on insurance receivables and cash collections, an aftershock of the Change Healthcare disruption. Kevin Taggart, managing partner at Mertz Taggart, put the mood plainly: “We are seeing a trend of fewer deal announcements.”
Sellers who used to get by on a growth story and a clean chart audit now face buyers who want SAMHSA correspondence, DEA registration histories, state survey findings, and payer SIU letters loaded into the data room on day one. Advisors who cannot connect those documents to price and to reps and warranties are not really doing M&A advisory. They are doing brokerage.
Buy-side: pricing the regulatory stack, not just the EBITDA
On the buy-side, our job is to find every reason the model overstates value before the LOI is signed. That means reading the actual state license file, not the summary. It means pulling the DEA registration for every OTP location and confirming buprenorphine authority under 42 CFR Part 8. It means reading The Joint Commission or CARF International survey reports, not just the certificate on the wall.
The regulatory stack drives the price adjustment. A few examples of what we have seen convert directly to purchase price reductions or indemnity holdbacks:
- EKRA exposure in marketing contracts. The Ninth Circuit issued two opinions interpreting EKRA in July 2025, and the law still lacks implementing regulations from DOJ. A percentage-of-collections rep arrangement is a real indemnity item. EKRA violations carry a maximum fine of $200,000 and up to 10 years imprisonment per occurrence under 18 U.S.C. § 220(a).
- 42 CFR Part 2 consent flow. Buyers acquiring an SUD program inherit every prior disclosure. If the target cannot demonstrate valid patient consents, the buyer is buying a settlement.
- CHOW licensure timing. In Florida, an AHCA change of ownership can pause billing if the application is not sequenced correctly. In Texas, HHSC has its own timing. In Colorado, the BHA licensure regime added transition steps that many 2024 deals underestimated.
- Payer contracts and Conditions of Participation. CMS Conditions of Participation and commercial network agreements often contain change-of-control clauses that require re-credentialing. A missed notification can trigger a 90-day payment pause.
Each of these gets a number attached: purchase price adjustment, escrow, specific indemnity, or walk. That is the work.
Sell-side: de-risking the asset 12 to 24 months before the process
Sell-side advisory in behavioral health starts long before the confidential information memorandum. The founder who calls us six months before a targeted close has already given up negotiating room. The founder who calls 18 months out can fix the findings that would otherwise sit in a Q of E adjustment.
The pre-market punch list usually includes: closing open state survey citations with documented corrective action; refreshing accreditation with The Joint Commission or CARF ahead of the next survey window; confirming DEA and SAMHSA OTP registrations are current at every physical address; reconciling 42 CFR Part 2 consent forms to actual disclosures; converting any 1099 clinician relationships that create EKRA or AKS risk; and building a payer contract matrix that maps effective dates, timely filing windows, and utilization management carve-outs. The SAMHSA N-SUMHSS 2023 report captured 20,681 substance use and mental health facilities, which tells you the buyer universe is large but the quality tier that trades at premium multiples is not.
A quality-of-earnings that survives buyer scrutiny in this market requires clean revenue integrity. Sell-side advisors who ignore denial trends, ASAM level of care documentation, and medical necessity criteria are handing the buyer a repricing lever. We would rather find it first and fix it than defend a number we cannot substantiate.
How compliance findings translate to reps, warranties, and escrow
This is where most competitor advisors stop and where AHS starts. A finding is not just a finding. It is a line in the purchase agreement.
- Specific indemnity vs. General indemnity. An open OIG or state SIU audit gets carved out into a specific indemnity with a longer survival period and a separate escrow, not the general basket. Buyers who accept a general indemnity for a known audit are underwriting the seller’s risk with their own capital.
- Escrow sizing. When we see a suspect marketing agreement that predates the current EKRA case law, the escrow needs to reflect potential per-occurrence exposure, not a rounded percentage of purchase price. DOJ has actively prosecuted South Florida addiction treatment operators under EKRA, the Anti-Kickback Statute, and wire fraud statutes, and those prosecutions inform how we size the number.
- R&W insurance underwriting. R&W carriers exclude known matters. They also increasingly exclude 42 CFR Part 2 and EKRA if the diligence file is thin. Sellers who complete the compliance work early get better R&W terms and lower retentions.
- CHOW conditions to closing. Florida AHCA, Texas HHSC, and Colorado BHA each have their own CHOW cadence. State approval sequencing belongs in the purchase agreement as a condition precedent, not a post-close obligation.
Advisors who tie the compliance file to the deal document earn their fee twice. Advisors who treat regulatory diligence as a checklist hand value to the other side of the table.
Frequently asked questions
What is the difference between buy-side and sell-side M&A advisory in behavioral health?
Buy-side advisors work for the acquirer and focus on identifying regulatory, clinical, and financial risks that support price reductions, indemnities, or a decision to walk. Sell-side advisors work for the seller and focus on de-risking the asset, running a confidential process, and defending value through diligence. Both require deep knowledge of SAMHSA, DEA, state licensing authorities, and the payer environment. A generalist healthcare banker without behavioral health specialization will miss the items that actually move price.
How long does regulatory due diligence take for a behavioral health acquisition?
Plan on 6 to 10 weeks for a multi-site SUD or mental health platform, longer if OTP registrations, CON approvals, or open state survey findings are involved. Deals with 42 CFR Part 2 exposure, EKRA questions, or pending payer audits routinely stretch further. Buyers should not sign a purchase agreement before receiving all state license files, all TJC or CARF survey reports for the last three cycles, DEA registration confirmations for every location, and the payer SIU correspondence log.
What licensure and accreditation issues most commonly kill or reprice a behavioral health deal?
Unresolved state survey citations, a probationary accreditation status with The Joint Commission or CARF International, DEA registration gaps at OTP sites, HIPAA breaches reported to OCR that were not disclosed in the data room, and CHOW timing risk in states like Florida (AHCA), Texas (HHSC), and Colorado (BHA). Any of these can either move the price or push the closing calendar into a payer contract renewal window the buyer did not model.
How do EKRA and 42 CFR Part 2 affect deal structure and reps and warranties?
EKRA exposure typically produces a specific indemnity, a dedicated escrow, and a longer survival period, because the statute carries up to $200,000 in fines and 10 years imprisonment per occurrence. 42 CFR Part 2 exposure typically produces a rep on consent adequacy, an indemnity for prior unauthorized disclosures, and, in some cases, a carve-out from R&W insurance coverage. Sophisticated buyers ask for both.
When should a founder engage a sell-side advisor before going to market?
Twelve to twenty-four months before the intended close. That window lets the founder close open findings, refresh accreditation, clean up marketing agreements that carry EKRA risk, convert problematic contractor relationships, and produce two to three quarters of clean, buyer-ready financials. Founders who wait until six months out generally take a discount they did not need to take.
References
- Mertz Taggart Q4 2025 Behavioral Health M&A Report (summary)
- Behavioral Health Business: Behavioral Health Dealmaking Dips to Pre-Pandemic Levels (Aug 2025)
- SAMHSA 2023 N-SUMHSS Annual Release
- Davis Wright Tremaine: First Guilty Plea Under EKRA (18 U.S.C. § 220)
- Holland & Knight: Ninth Circuit Clarifies Permissible Marketing Activity Under EKRA (Aug 2025)
- National Law Review: DOJ Focused on Toxicology Testing, EKRA and AKS Violations
- 42 CFR Part 2 (eCFR): Confidentiality of Substance Use Disorder Patient Records